HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review)

International Journal of Oncology

Volumn 27, Issue 5, 2005, Pages 1401-1409

  Fritz, Gerhard ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Drug and radiation resistance; Genotoxic stress response; HMG CoA reductase inhibitors (statins); Metastasis; Protein prenylation; Small GTPases

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

CELL ADHESION; CELL DEATH; CELL PROLIFERATION; DRUG EFFECT; HUMAN; IONIZING RADIATION; METASTASIS; NEOPLASM; PHYSIOLOGY; REVIEW;

CELL ADHESION; CELL DEATH; CELL PROLIFERATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASM METASTASIS; NEOPLASMS; RADIATION, IONIZING; RAS GTPASE-ACTIVATING PROTEINS; RHO GTP-BINDING PROTEINS;

EID: 30644478973     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.5.1401     Document Type: Review

References (142)

1. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA and Liao JK: Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885,1998.
2. Blauw GJ, Lagaay AM and Westendorp RG: Statins for prevention of stroke. Lancet 352: 144, 1998.
3. Farnier M and Davignon J: Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82: 3J-10J, 1998.
4. Endres M and Laufs U: Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2708-2711, 2004.
5. Cox AD and Der CJ: Protein prenylation: more than just glue? Curr Opin Cell Biol 4: 1008-1016, 1992.
6. Glomset JA, Gelb MH and Farnsworth CC: Prenyl proteins in eukaryotic cells: a new type of membrane anchor. TIBS 15: 139-142,1990.
7. Adamson P, Marshall CJ, Hall A and Tilbrook PA: Posttranslational modifications of p21rho proteins. J Biol Chem 267: 20033-20038,1992.
8. Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
9. Walker K and Olson MF: Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15: 62-68,2005.
10. Crisby M, Carlson LA and Winblad B: Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 16: 131-136,2002.
11. Waldman A and Kritharides L: The pleiotropic effects of HMGCoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 63: 139-152,2003.
12. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003.
13. Kusarna T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M and Nakamura H: 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317,2002.
14. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V and Katoh A: Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13: 314-324,1993.
15. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25,1999.
16. Jakobisiak M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632,1991.
17. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D and Slingerland J: Gl control in mammalian cells. J Cell Sci Suppl 18: 69-73,1994.
18. Vogt A, Qian Y, McGuire TF, Hamilton AD and Sebti SM: Protein geranylgeranylation, not farnesylation, is required for the Gl to S phase transition in mouse fibroblasts. Oncogene 13: 1991-1999,1996.
19. Naderi S, Blomhoff R, Myklebust J, Smeland EB, Erikstein B, Norum KR and Blomhoff HK: Lovastatin inhibits Gl/S transition of normal human B-lymphocytes independent of apoptosis. Exp Cell Res 252: 144-153,1999.
20. Cooper S: Reappraisal of Gl-phase arrest and synchronization by lovastatin. Cell Biol Internat 26: 715-727, 2002.
21. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim S J and Trepel JB: Inhibition of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase pathway induces p53- independent transcriptional regulation of p21(WAFl/CIPl) in human prostate carcinoma cells. J Biol Chem 273: 10618-10623, 1998.
22. Muller C, Kiehl MG, van de Loo J and Koch OM: Lovastatin induces p21WAFl/Cipl in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis and growth inhibition. Int J Mol Med 3: 63-68, 1999.
23. Vidal A, Millard SS, Miller JP and Koff A: Rho activity can alter the translation of p27 mRNA and is important for RasV12- induced transformation in a manner dependent on p27 status. J Biol Chem 277: 16433-16440, 2002.
24. Adnane J, Bizouarn FA, Qian Y, Hamilton AD and Sebti SM: p21(WAFl/CIPl) is up-regulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Spl-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 18: 6962-7690,1998.
25. Rao S, Porter DC, Chen X, Herliczek T, Lowe M and Keyomarsi K: Lovastatin-mediated Gl arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96: 7797-7802, 1999.
26. Sebti SM, Tkalcevic GT and Jani JP: Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 3: 141-147, 1991.
27. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M and Aizawa R: Chemoprevention by pravastatin, a 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-Nnitrosourea- induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87: 798-804,1996.
28. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K and Ishikawa C: Prevention of 1,2-dimethylhydrazine- induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 15: 2045-2048, 1994.
29. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMGCoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519,2002.
30. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD and Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 7: 2067-2075, 2001.
31. Choi JW and Jung SE: Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther 289: 572-579,1999.
32. Cafforio P, Dammacco F, Gernone A and Silvestris F: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891,2005.
33. Feng C, Ye C, Liu X, Ma H and Li M: Beta4 integrin is involved in statin-induced endothelial cell death. Biochem Biophys Res Commun 323: 858-864, 2004.
34. Kaneta S, Satoh K, Kano S, Kanda M and Ichihara K: All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170:237-243,2003.
35. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD and Harlan JM: Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277: 15309-15316, 2002.
36. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, Di Pasquale G and Corica F: Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 370: 201-203,1999.
37. Cafforio P, Dammacco F, Gernone A and Silvestris F: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis26: 883-891,2005.
38. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001.
39. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E and Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491,1996.
40. Gliemroth J, Zulewski H, Arnold H and Terzis AJ: Migration, proliferation and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev 26: 117-124, 2003.
41. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K and Tonn JC: Inhibition of Ras farnesylation by lovastatin leads to down-regulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20: 2761-2771, 2000.
42. Kort WJ, Hulsmann WC and Stenman TE: Modulation of metastatic ability by inhibition of cholesterol synthesis. Clin Exp Metastasis 7: 517-523,1989.
43. Mehta N, Hordines J, Sykes D, Doerr RJ and Cohen S A: Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clin Exp Metastasis 16: 587-594,1998.
44. Nubel T, Dippold W, Kleinert H, Kaina B and Fritz G: Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 18: 140-142,2004.
45. Nubel T, Dippold W, Kaina B and Fritz G: Ionizing radiationinduced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid. Carcinogenesis 25: 1335-1344,2004.
46. Wang IK, Lin-Shiau SY and Lin JK: Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 59: 245-254, 2000.
47. Krause T and Turner GA: Are selectins involved in metastasis? Clin Exp Metastasis 17: 183-192,1999.
48. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS and Gomez DE: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93,1998.
49. Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A and Jakobisiak M: Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81: 560-567,1999.
50. Simons M: Molecular multitasking: statins lead to more arteries, less plaque. Nat Med 6: 965-966, 2000.
51. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC and Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
52. Weis M, Heeschen C, Glassford AJ and Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 105: 739-745,2002.
53. Urbich C, Dernbach E, Zeiher AM and Dimmeler S: Doubleedged role of statins in angiogenesis signaling. Circ Res 90: 737-744,2002.
54. Ungvari Z, Pacher P and Csiszar A: Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF? Med Hypoth 58: 85-86, 2002.
55. Newman TB and Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 275: 55-60,1996.
56. Dalen JE and Dalton WS: Does lowering cholesterol cause cancer? JAMA 275: 67-69,1996.
57. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W and Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622,1998.
58. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR and Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009,1996.
59. Group TLS: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359: 1379-1387, 2002.
60. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C and Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630,2002.
61. Blais L, Desgagne A and LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368, 2000.
62. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ and Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394,2004.
63. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891,2001.
64. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH and Kang WK: Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19: 81-83,2001.
65. Larner J, Jane J, Laws E, Packer R, Myers C and Shaffrey M: A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21: 579-583,1998.
66. Kjoller L and Hall A: Signaling to Rho GTPases. Exp Cell Res 253: 166-179,1999.
67. Van Aelst L and D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 11: 2295-2322,1997.
68. Bourne HR, Sanders DA and McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127,1991.
69. Zhang FL and Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269,1996.
70. Gelb MH, Scholten JD and Sebolt Leopold JS: Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol 2: 40-48, 1998.
71. Gosser YQ, Nomanbhoy TK, Aghazadeh B, Manor D, Combs C, Cerione RA and Rosen MK: C-terminal binding domain of Rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases. Nature 387: 814-819,1997.
72. Hoffman GR, Nassar N and Cerione RA: Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 100: 345-356,2000.
73. Olofsson B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 11: 545-554,1999.
74. Cox AD and Der C J: Ras family signaling: therapeutic targeting. Cancer Biol Ther 1: 599-606, 2002.
75. Campbell PM and Der CJ: Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14: 105-114, 2004.
76. Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 84: 57-80,2002.
77. Hall A: Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998.
78. Ridley AJ and Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399,1992.
79. Ridley AJ, Paterson HF, Johnston CL, Diekmann D and Hall A: The small GTP-binding protein rac regulates growth factor induced membrane ruffling. Cell 70: 401-410,1992.
80. Kozma R, Ahmed S, Best A and Lim L: The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. Mol Cell Biol 15: 1942-1952,1995.
81. Cox D, Chang P, Zhang Q, Reddy PG, Bokoch GM and Greenberg S: Requirements for both Racl and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J Exp Med 186: 1487-1494,1997.
82. Caron E and Hall A: Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282:1717-1721,1998.
83. Nobes CD and Hall A: Rho GTPases control polarity, protrusion and adhesion during cell movement. J Cell Biol 144: 1235-1244, 1999.
84. Braga VM: Small GTPases and regulation of cadherin dependent cell-cell adhesion. Mol Pathol 52: 197-202,1999.
85. Wojciak Stothard B, Williams L and Ridley AJ: Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 145: 1293-1307, 1999.
86. Clark EA, King WG, Brugge JS, Symons M and Hynes RO: Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol 142: 573-586,1998.
87. Coso AA, Chiariello M, Yu J-C, Teramoto H, Crespo P, Xu N, Miki T and Gutkind JS: The small GTP-binding proteins Racl and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81: 1137-1146, 1995.
88. Minden A, Lin A, Claret F-X, Abo A and Karin M: Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157,1995.
89. Esteve P, Embade N, Perona R, Jimenez B, Del Peso L, Leon J, Arends M, Miki T and Lacal JC: Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway. Oncogene 17: 1855-1869, 1998.
90. Qiu R-G, Chen J, Kirn D, McCormick F and Symons M: An essential role for Rac in Ras transformation. Nature 374: 457-459, 1995.
91. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF and Der CJ: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10: 2289-2296,1995.
92. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS and Der CJ: Activation of Racl, Rho A and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15: 6443-6453, 1995.
93. Olson MF, Paterson HF and Marshall CJ: Signals from Ras and Rho GTPases interact to regulate expression of p21Wafl/Cipl. Nature 394: 295-299, 1998.
94. Fritz G, Brachetti C, Bahlmann F, Schmidt M and Kaina B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87: 635-644, 2002.
95. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H and Fukumoto M: Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77: 147-152, 1998.
96. Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535,2000.
97. Yoshioka K, Matsumura F, Akedo H and Itoh K: Small GTPbinding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 273: 5146-5154,1998.
98. Stam JC, Michiels F, van der Kammen RA, Moolenaar WH and Collard JG: Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J 17: 4066-4074,1998.
99. Adnane J, Muro-Cacho C, Mathews L, Sebti SM and Munoz- Antonia T: Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 8: 2225-2232, 2002.
100. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003.
101. Schmitz AAP, Govek EE, Böttner B and van Aelst L: Rho GTPases: signaling, migration and invasion. Exp Cell Res 261: 1-12,2000.
102. Koch G, Benz C, Schmidt G, Olenik C and Aktories K: Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther 283: 901-909,1997.
103. Laufs U and Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271,1998.
104. Gnad R, Kaina B and Fritz G: Rho GTPases are involved in the regulation of NF-KB by genotoxic stress. Exp Cell Res 264: 244-249,2001.
105. Bardeleben R, Kaina B and Fritz G: Ultraviolet light-induced apoptotic death is impaired by the HMG-CoA reductase inhibitor lovastatin. Biochem Biophys Res Commun 307: 401-407, 2003.
106. Gnad R, Aktories K, Kaina B and Fritz G: Inhibition of protein isoprenylation impairs rho-regulated early cellular response to genotoxic stress. Mol Pharmacology 58: 1389-1397, 2000.
107. Miller AC, Kariko K, Myers CE, Clark EP and Samid D: Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53: 302-307,1993.
108. Canman CE and Kastan MB: Three paths to stress relief. Nature 384: 213-214,1996.
109. Cortez D, Guntuku S, Qin J and Elledge S J: ATR and ATRIP: partners in checkpoint signaling. Science 294: 1713-1716, 2001.
110. Durocher D and Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13: 225-231,2001.
111. .Ichijo H: From receptors to stress-activated MAP kinases. Oncogene 18: 6087-6093,1999.
112. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331,1995.
113. Verheij M, Bose R, Lin XH, et al: Requirement for ceramideinitiated SAPK/JNK signaling in stress-induced apoptosis. Nature 380: 75-79, 1996.
114. Sanchez Perez I, Murguia JR and Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16: 533-540,1998.
115. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112: 974-985, 2004.
116. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R and Mercola D: The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272: 14041-14044,1997.
117. Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274: 784-787,1996.
118. Kaina B, Haas S and Kappes H: A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res 57: 2721-2731,1997.
119. Fei P and El-Deiry WS: P53 and radiation responses. Oncogene 22:5774-5783,2003.
120. Lakin ND and Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999.
121. Miller AC and Samid D: Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 60: 249-254,1995.
122. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A and Jakobisiak M: Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6: 2044-2052,2000.
123. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B and Meinhardt G: The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104: 1825-1832, 2004.
124. Lebowitz PF and Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17: 1439-1445, 1998.
125. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM and Muschel RJ: Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58: 1754-1761,1998.
126. Smalley KS and Eisen TG: Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105: 165-175,2003.
127. Adjei AA, Davis JN, Bruzek LM, Erlichman C and Kaufmann SH: Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7: 1438-1445,2001.
128. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D and Bosia A: Nitric oxide reverts the resistance to Doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525,2005.
129. Esteve P, Del-Peso L and Lacal JC: Induction of apoptosis by rho in HIH3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Oncogene 11: 2657-2665, 1995.
130. Liu A-X, Cerniglia GJ, Bernhard EJ and Prendergast GC: RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci USA 98: 6192-6197,2001.
131. Fritz G and Kaina B: Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem Biophys Res Commun 268: 784-789, 2000.
132. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G and Jakobisiak M: Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100: 111-118,2002.
133. Bardeleben RV, Dunkern T, Kaina B and Fritz G: The HMGCoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med 10: 473-479,2002.
134. Feleszko W, Zagozdzon R, Golab J and Jakobisiak M: Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411, 1998.
135. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG and Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5: 2223-2229,1999.
136. Holstein SA and Hohl RJ: Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25: 651-660, 2001.
137. Holstein SA and Hohl RJ: Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1: 141-149,2001.
138. Fritz G, Brachetti C and Kaina B: Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage. Int J Radiat Biol 79:601-610,2003.
139. Lishner M, Bar-Sef A, Elis A and Fabian I: Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 49: 319-324,2001.
140. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P and Fumagalli R: Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyi)- N-nitrosourea and beta-interferon on human glioma cells. Cancer Res 52: 4348-4355,1992.
141. .Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
142. Wang W, Collie-Duguid E and Cassidy J: Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 531: 415-420, 2002.